ArticleClinical, cosmetic and investigational dermatology2026
Differential expression of Wnt5a and β-Catenin in Keratoacanthoma, Verrucous Carcinoma and Well-Differentiated Squamous Cell Carcinoma.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carcinoma Cuniculatum of the Hand: A Case Report.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Verrucous carcinoma (VC) are always considered to be a variant of well-differentiated squamous cell carcinoma (SCC). If Keratoacanthoma (KA) is a variant of well-differentiated SCC, it is controversial currently. Both β-catenin and Wnt5a are key factors in the classical and non-classical Wnt signaling pathways, which are often used in the differential diagnosis of benign and malignant tumors. However, the expression of these two factors in these three diseases remains unclear. The goal of the current study was to explore the expression of β-catenin and Wnt5a in KA, VC, and well-differentiated SCC and to determine their value in differential diagnosis. Methods: Twenty samples were collected from VC lesions, 30 from KA lesions, and 30 from cutaneous well-differentiated SCC lesions. The expression of Wnt5a and β-catenin in paraffin-embedded tissue sections was analyzed by immunohistochemistry. The histo (H) score was used to evaluate positive cases. Results: There were no statistically significant differences in sex or age between KA, VC, and well-differentiated SCC patients ( Conclusion: In this study, the differential expression of Wnt5a and β-catenin suggests that the benign tumor KA and well-differentiated SCC may be two distinct entities. We identified that Wnt5a and β-catenin could be used as adjuvant immunohistochemical markers for the differential diagnosis of KA from well-differentiated SCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.